Geisinger Health System, Indivumed Team on Personalized Cancer Projects | GenomeWeb

NEW YORK (GenomeWeb) – The Geisinger Health System has struck a partnership with German personalized cancer services company Indivumed to collect and study patient samples and develop targeted treatments, the partners said today.

The agreement will enable Indivumed and Geisinger to collect samples from consenting patients who are already undergoing a surgical tumor resection. The partners will store portions of those tissue, blood, or urine samples at Geisinger via the MyCode repository, and in an Indivumed bank, where they will be analyzed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.